Elicio Therapeutics, Inc.
ELTX
$11.68
-$0.50-4.11%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
Zacks Investment Research
3/18/2026
-
Zacks Investment Research
3/18/2026
-
Tickeron - Technical Analysis
3/17/2026
-
TipRanks Financial Blog
3/17/2026
-
Globe Newswire
3/14/2026
-
Tickeron - Technical Analysis
3/13/2026
-
Tickeron - Stocks
3/13/2026
-
Tickeron - Stocks
3/13/2026
-
Tickeron - Stocks
3/12/2026
-
SeekingAlpha.com: All News
3/12/2026
-
Globe Newswire
3/11/2026
-
Nasdaq News: Stocks
3/4/2026
-
Tickeron - Technical Analysis
2/27/2026
-
TipRanks Financial Blog
2/27/2026
-
The Fly
2/25/2026
-
Globe Newswire
2/18/2026
-
The Fly
2/18/2026
-
The Fly
2/18/2026
-
Globe Newswire
2/11/2026
-
Tickeron - Stocks
2/10/2026
-
Simply Wall St
2/10/2026
-
Tickeron - Stocks
2/10/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 12, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 209 0050
Address
451 D Street
5th Floor - Suite 501
Boston, MA 02210
5th Floor - Suite 501
Boston, MA 02210
Country
Year Founded
--
Business Description
Sector
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted...
more